TREATMENT WITH HIGHLY PURIFIED EICOSAPENTAENOIC ACID AS FREE FATTY ACID IMPROVES INFLAMMATION, AFFECTS COLONIC DIFFERENTIATION MARKERS AND MICROBIOTA IN PATIENTS WITH ULCERATIVE COLITIS

摘要

This present invention relates to the use of eicosapentaenoic acid (EPA) for the treatment of ulcerative colitis (UC), and more particularly, the use of highly purified eicosapentaenoic acid as free fatty acids (EPA-FFA) having a purity of at least 95% for reducing inflammation in a subject suffering from ulcerative colitis and wherein the levels of IL-10 and SOCS3 are increased and the microbiome of the intestinal mucosal tissue is favorably modulated.